NCT02801357View on ClinicalTrials.gov

Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Substance Withdrawal SyndromeOpiate AddictionOpiate Dependence
Interventions
DRUG

lofexidine administration in subjects seeking buprenorphine dose reduction

Trial Locations (1)

66212

Overland Park

All Listed Sponsors
lead

USWM, LLC (dba US WorldMeds)

INDUSTRY

NCT02801357 - Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction | Biotech Hunter | Biotech Hunter